News 17.12.2020 Zurich-Schlieren, Switzerland, December 17, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio...
News 10.12.2020 Schlieren and St. Gallen, Switzerland, December 10, 2020 - The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced that Prof. Dr. med. Wolfang Korte who leads the Center for Laboratory Medicine will present new data from the implementation of Proclarix® in their laboratory...
News 02.12.2020 Zurich-Schlieren, Switzerland and Frankfurt am Main, Germany, December 2, 2020 - The University Hospital Frankfurt MVZ (Medical Outpatient Care Center) GmbH, and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, is made routinely available in Germany. ”Proclarix is an innovative...
News 23.11.2020 Zurich-Schlieren, Switzerland, November 23, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep),...
News 20.11.2020 Schlieren (Zurich), Switzerland, November 20, 2020 – Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics This Week for outstanding innovations in the field, for its Fibrin-PTH (KUR-113) technology, which delivers targeted and controlled bone formation. The prestigious...